Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial

Journal of Substance Abuse Treatment
Seyed Mohammad AssadiPadideh Ghaeli

Abstract

In recent years, interest in shortening of opioid detoxification has increased with the rising demands to find more cost-effective approaches for treatment of opioid dependence. This study was designed to evaluate the efficacy of administration of high doses of buprenorphine during 24 h in the management of acute opioid withdrawal. A total of 40 treatment-seeking opioid dependents were admitted and randomly assigned to two groups in a double blind, parallel trial. Buprenorphine was administered intramuscularly. Twenty patients received 12 mg buprenorphine in 24 h and the remaining 20 patients treated with conventional doses of buprenorphine tapered down over 5 days. Variables that were assessed included retention in treatment, rates of successful detoxification, the Subjective Opiate Withdrawal Scale (OOWS) scores, the Objective Opiate Withdrawal Scale (SOWS) scores, intensity of craving, drug side effects, and levels of hepatic enzymes (ALT and AST). There was no significant difference between the two groups on most variables. The main difference was in the time that maximal withdrawal symptoms occurred, which in the experimental protocol group appeared early while in the conventional protocol group appeared later during the d...Continue Reading

References

Aug 1, 1978·The International Journal of the Addictions·F R Goldman, C I Thistel
Jul 1, 1976·Anesthesia and Analgesia·G R Gay, D S Inaba
Mar 1, 1988·British Journal of Addiction·E Senay
Jan 1, 1987·The American Journal of Drug and Alcohol Abuse·L HandelsmanP D Kanof
Oct 6, 1997·Annals of Internal Medicine·P G O'ConnorB J Rounsaville
Jan 23, 1998·JAMA : the Journal of the American Medical Association·P G O'Connor, T R Kosten
Mar 23, 1999·European Addiction Research·J S Akhurst
Mar 23, 1999·JAMA : the Journal of the American Medical Association·E C StrainM L Stitzer
Jun 22, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·I H Franken, V M Hendriks
Aug 26, 1999·Drug and Alcohol Dependence·S H ArmenianM L Stitzer
Oct 21, 1999·Drug and Alcohol Dependence·A UmbrichtK L Preston
Jun 23, 2000·Biological Psychiatry·R S SchottenfeldT R Kosten
Jul 31, 2001·Journal of Psychoactive Drugs·I Kutz, V Reznik
Mar 16, 2002·Addiction·Linda R GowingJason M White

❮ Previous
Next ❯

Citations

Dec 18, 2008·Journal of General Internal Medicine·Joshua D LeeMarc N Gourevitch
Mar 22, 2007·Journal of Psychoactive Drugs·Kathleen Ang-LeePatricia C Knox
Sep 20, 2012·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Aaron D FoxChinazo O Cunningham
Jul 1, 2012·Industrial Psychiatry Journal·Siddharth Sarkar, Surendra K Mattoo
Mar 16, 2006·The Journal of Pharmacy and Pharmacology·Kuo-Sheng LiuJhi-Joung Wang
Dec 1, 2010·Asian Journal of Psychiatry·Somsubhra ChattopadhyaySharmistha Debnath
Aug 11, 2017·The American Journal of Drug and Alcohol Abuse·Gregory RudolfVania Rudolf
Jun 22, 2018·The Cochrane Database of Systematic Reviews·Afarin Rahimi-MovagharMasoumeh Amin-Esmaeili
Nov 15, 2013·The Journal of Pharmacology and Experimental Therapeutics·D Andrew TompkinsEric C Strain
Feb 22, 2017·The Cochrane Database of Systematic Reviews·Linda GowingDalitso Mbewe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved